Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Petukhova, Elena O.a | Mukhamedshina, Yana O.a; b | Salafutdinov, Ilnur I.a; b | Garanina, Ekaterina E.b | Kaligin, Maxim S.b | Leushina, Alina V.a | Rizvanov, Albert A.b | Reis, Helton J.c | Palotás, Andrásb; d; * | Zefirov, Andrey L.a | Mukhamedyarov, Marat A.a; *
Affiliations: [a] Kazan State Medical University, Kazan, Russia | [b] Kazan Federal University, Kazan, Russia | [c] Universidade Federal de Minas Gerais, Belo Horizonte, Brazil | [d] Asklepios-Med, Szeged, Hungary
Correspondence: [*] Correspondence to: Prof. Dr. Marat Mukhamedyarov and prof. Dr. András Palotás, Kazan State Medical University, Kazan, E-mail: Russia.marat.muhamedyarov@kazangmu.ru and palotas@asklepios-med.eu.
Abstract: Background/Objective:Alzheimer’s disease (AD) is a progressive incurable neurodegenerative disorder. Glial cell line-derived neurotrophic factor (GDNF) is a prominent regulator of brain tissue and has an impressive potential for use in AD therapy. While its metabolism is still not fully understood, delivering neuropeptides such as GDNF via umbilical cord blood mononuclear cells (UCBMCs) to the sites of neurodegeneration is a promising approach in the development of innovative therapeutic avenues. Methods:UCBMCs were transduced with adenoviral vectors expressing GDNF and injected into AD transgenic mice. Various parameters including homing and survival of transplanted cells, expression of GDNF and synaptic proteins, as well as spatial memory were evaluated. Results:UCBMCs were observed in the hippocampus and cortex several weeks after transplantation, and their long-term presence was associated with improved spatial memory. Post-synaptic density protein 95 (PSD-95) and synaptophysin levels in the hippocampus were also effectively restored following the procedure in AD mice. Conclusions:Our data indicate that gene-cell therapy with GDNF-overexpressing UCBMCs may produce long-lasting neuroprotection and stimulation of synaptogenesis. Such adenoviral constructs could potentially possess a high therapeutic potential for the treatment of AD.
Keywords: Alzheimer’s disease, glial cell line-derived neuro-trophic factor, post-synaptic density protein 95, synaptophysin, umbilical cord blood mono-nuclear cells
DOI: 10.3233/JAD-190150
Journal: Journal of Alzheimer's Disease, vol. 69, no. 2, pp. 443-453, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl